Alpha Synuclein Toxicity and Non-Motor Parkinson's

Area of Science:

• Neuroscience
• Neuropathology
• Biomarker Discovery

Background:

• Parkinson's disease (PD) affects 1% of individuals over 60, characterized by dopaminergic neuron loss and alpha-synuclein (αSyn) Lewy bodies.
• αSyn pathology contributes to both motor and non-motor symptoms (NMS) in PD, with NMS often preceding motor diagnosis.
• NMS encompass a wide range of conditions including sensory, psychiatric, sleep, and autonomic dysfunctions.

Purpose of the Study:

• To review recent findings on the role of αSyn deposits in prodromal non-motor symptoms of Parkinson's disease.
• To highlight the potential of detecting toxic αSyn species as early biomarkers for PD.

Main Methods:

• Literature review of recent research on αSyn pathology and its association with NMS in PD.
• Analysis of studies investigating αSyn detection in biofluids and peripheral tissues.

Main Results:

• αSyn aggregation and spread are implicated in the development of various NMS, including olfactory loss, constipation, and REM sleep behavior disorder.
• Emerging evidence suggests that toxic αSyn species can be detected in peripheral tissues and biofluids.
• These findings underscore the link between αSyn pathology and the diverse clinical manifestations of PD.

Conclusions:

• αSyn plays a crucial role in the pathogenesis of both motor and non-motor symptoms in Parkinson's disease.
• Early detection of pathological αSyn species in accessible biofluids and biopsies holds promise for developing novel diagnostic biomarkers for PD.
• Further research is warranted to validate these potential biomarkers for clinical application.